454 related articles for article (PubMed ID: 34376554)
1. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Dorff T; Hirasawa Y; Acoba J; Pagano I; Tamura D; Pal S; Zhang M; Waitz R; Dhal A; Haynes W; Shon J; Scholz M; Furuya H; Chan OTM; Huang J; Rosser C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376554
[TBL] [Abstract][Full Text] [Related]
2. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
3. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine.
Madan RA; Redman JM; Karzai F; Dahut WL; Cordes L; Fakhrejahani F; Vu T; Sheikh N; Schlom J; Gulley JL
J Immunother; 2023 May; 46(4):145-151. PubMed ID: 36821354
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Rodriguez-Vida A; Maroto P; Font A; Martin C; Mellado B; Corbera A; Orrillo M; Reig O; Querol R; Rios-Hoyo A; Cano L; Alonso J; Martinez G; Galtes S; Taus A; Martinez-Garcia M; Juanpere N; Juan O; Bellmunt J
Br J Cancer; 2023 Jan; 128(1):21-29. PubMed ID: 36289372
[TBL] [Abstract][Full Text] [Related]
5. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
Redman JM; Steinberg SM; Gulley JL
J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N; Koyama T; Sato J; Yoshida T; Sudo K; Iwasa S; Kondo S; Yonemori K; Kawasaki A; Satake K; Shibata S; Shimizu T
Cancer Chemother Pharmacol; 2024 Jan; ():. PubMed ID: 38206370
[TBL] [Abstract][Full Text] [Related]
7. The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
Mouraviev V; Mariados N; Albala D; Concepcion RS; Shore ND; Sims RB; Emberton M; Pieczonka CM
Rev Urol; 2014; 16(3):122-30. PubMed ID: 25337042
[TBL] [Abstract][Full Text] [Related]
8. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.
Graff JN; Chamberlain ED
Core Evid; 2015; 10():1-10. PubMed ID: 25565923
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.
Lasek W; Zapała Ł
Cent European J Urol; 2021; 74(3):300-307. PubMed ID: 34729217
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ; Piha-Paul SA; Medina T; Verschraegen CF; Varterasian M; Brennan AM; Riese RJ; Sokolovska A; Strauss J; Hava DL; Janku F
Clin Cancer Res; 2023 Jul; 29(13):2435-2444. PubMed ID: 37227176
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.
Hagihara K; Chan S; Zhang L; Oh DY; Wei XX; Simko J; Fong L
Oncoimmunology; 2019; 8(1):e1486953. PubMed ID: 30546940
[TBL] [Abstract][Full Text] [Related]
12. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
13. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC; Wang C; Teer JK; Toloza EM; Yao J; Kim S; Landin AM; Mullinax JE; Saller JJ; Saltos AN; Noyes DR; Montoya LB; Curry W; Pilon-Thomas SA; Chiappori AA; Tanvetyanon T; Kaye FJ; Thompson ZJ; Yoder SJ; Fang B; Koomen JM; Sarnaik AA; Chen DT; Conejo-Garcia JR; Haura EB; Antonia SJ
Nat Med; 2021 Aug; 27(8):1410-1418. PubMed ID: 34385708
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.
Naidoo J; Schreck KC; Fu W; Hu C; Carvajal-Gonzalez A; Connolly RM; Santa-Maria CA; Lipson EJ; Holdhoff M; Forde PM; Douville C; Riemer J; Barnes A; Redmond KJ; Kleinberg L; Page B; Aygun N; Kinzler KW; Papadopoulos N; Bettegowda C; Venkatesan A; Brahmer JR; Grossman SA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380662
[TBL] [Abstract][Full Text] [Related]
18. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Hack SP; Verret W; Mulla S; Liu B; Wang Y; Macarulla T; Ren Z; El-Khoueiry AB; Zhu AX
Ther Adv Med Oncol; 2021; 13():17588359211036544. PubMed ID: 34377158
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
